07/05/2013
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Drip bottle problem
Drug is indicated for symptomatic relief of gases
Janssen-Cilag recommends that the product is not administered directly into the patient's mouth
Mylicon: product should not be administered directly into the patient's mouth
DISCLOSURE
BRASILIA - The National Agency for Sanitary Surveillance (ANVISA) ordered the suspension of the distribution, trade and use, beyond the gathering of five batches of the drug Mylicon by problems in drip bottle. Determining resolution is published in this Thursday's Official Gazette The product is indicated for the relief of symptoms of excess gas in the digestive tract.
Lots of problems with Mylicon are PNL045, PNL046, PNL111, PNL132 and PPL001, packing with 75 milligrams. These products have been manufactured in November 2011 and are valid until November this year.
On its website, the product manufacturer, Janssen-Cilag, informs that the product has a new form of administration. "Due to the low possibility of loosening the dripper at the time the product cover is removed, the recommendation is that the product should not be administered directly into the patient's mouth." The company also reports that this recommendation will include the new version of the package insert. If in doubt, consumers can contact the Service Consumer Lab at 0800-7011851.
Read more about this topic in
© 1996-2013. All rights reserved Infoglobo Comunicação e Participações SA This material may not be published, broadcast, rewritten or redistributed without permission.
Source: The Globe - Online
Our news are taken in full from our partner sites. For this reason, we can not change the contents of the same even in cases of typos.
This article was translated by an automatic translation system, and was therefore not reviewed by people.